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Interferons (IFNs) inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication and might be valuable for SARS treatment.
In this study, we demonstrate that treatment of Vero E6 cells with interleukin-4 (IL-4) decreased the susceptibility of these cells to SARS-CoV
infection. In contrast to IFNs, IL-4 did not show antiviral activity when administered immediately after SARS-CoV infection, suggesting that IL-4
acts early during the SARS-CoV replication cycle. Indeed, binding of recombinant SARS-CoV spike protein to Vero E6 cells was diminished on
cells treated with IL-4, but also on cells exposed to IFN-γ. Consistent with these observations, IL-4 and IFN-γ downregulated cell surface
expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Besides diminished ACE2 cell surface expression, ACE2
mRNA levels were also decreased after treatment with these cytokines. These findings suggest that IL-4 and IFN-γ inhibit SARS-CoV replication
partly through downregulation of ACE2.
© 2006 Elsevier Inc. All rights reserved.Keywords: SARS-CoV; ACE2; Interferon-gamma; Interleukin-4Introduction
Severe acute respiratory syndrome (SARS) emerged late
2002/early 2003 in Guangdong Province, China, and spread
rapidly to several countries in Asia, North America and Europe,
causing disease in almost 8000 people, of whom nearly 10%
died. Only a few months after the first emergence of SARS, a
newly discovered coronavirus (CoV) was identified as its
etiological agent (Drosten et al., 2003; Ksiazek et al., 2003;
Peiris et al., 2003).
SARS-CoV is a positive stranded RNA virus with a genome
of about 30 kb in length that is structurally similar to that of
other group 2 coronaviruses (Marra et al., 2003; Rota et al.,
2003; Snijder et al., 2003). It enters the host cell by binding of
the spike (S) protein S1 domain to angiotensin-converting
enzyme 2 (ACE2), the SARS-CoV receptor (Li et al., 2003).
Subsequently, the S2 domain fuses with the cellular membrane
(Liu et al., 2004). ACE2 is a component of the renin–
angiotensin system and mainly involved in the regulation of⁎ Corresponding author. Fax: +31 10 4089485.
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doi:10.1016/j.virol.2006.06.011heart function and blood pressure (Boehm and Nabel, 2002;
Crackower et al., 2002). It is expressed in vascular endothelia,
heart, kidney and testis, but also in epithelia of the small
intestine and in alveolar epithelial cells (Donoghue et al., 2000;
Hamming et al., 2004; Harmer et al., 2002). Recently it was
shown that ACE2 also acts as a receptor for human coronavirus
NL63 (HCoV-NL63) (Hofmann et al., 2005).
SARS-CoV replicates predominantly in the lower respiratory
tract and causes diffuse alveolar damage, leading to severe
respiratory distress (Kuiken et al., 2003; Nicholls et al., 2003).
Treatment of SARS patients was mainly based on the use of
ribavirin and corticosteroids, but the efficacy of these drugs has
not been proven. Several groups have examined the antiviral
effect of interferons (IFNs) against SARS-CoV. In vitro studies
have shown that human recombinant IFNs inhibit SARS-CoV
replication and that IFN-β and IFN-γ combined have a
synergistic antiviral effect against this virus (Cinatl et al.,
2003; Morgenstern et al., 2005; Sainz et al., 2004). Further-
more, we have demonstrated that pegylated IFN-α protected
type-1 pneumocytes from infection with SARS-CoV in
cynomolgous macaques (Haagmans et al., 2004). Usually
IFNs achieve their antiviral effect through the induction of
Fig. 2. Antiviral activity of IL-4 against HCoV-NL63. Titration of supernatant
after infection of Vero E6 cells with 105 TCID50 HCoV-NL63. Error bars
indicate standard errors.
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To further explore the antiviral effect of IFNs and other
cytokines specifically against SARS-CoV infection, we treated
Vero E6 cells with various amounts of IFN-γ, tumor necrosis
factor (TNF)-α or interleukin (IL)-4 and infected these cells
with SARS-CoV.
Results
Susceptibility of Vero E6 cells to SARS-CoV or HSV infection
after cytokine treatment
Vero E6 cells were treated with 1, 10 or 100 ng/ml of IL-4,
IL-10, IFN-γ, TNF-α or a combination of IFN-γ and TNF-α
and infected with SARS-CoVor herpes simplex virus (HSV)-1.
While treatment with TNF-α (Fig. 1A) or IL-10 (data not
shown) had no antiviral effect against SARS-CoV or HSV-1,
pretreatment with IFN-γ (Fig. 1B) or a combination of IFN-γ
and TNF-α (Fig. 1C) dose dependently reduced the number of
infected cells per well after infection with either one of these
viruses, as demonstrated previously (Cinatl et al., 2003;
Feduchi et al., 1989). Surprisingly, recombinant human IL-4
also exerted SARS-CoV antiviral activity, which was not
observed against HSV infection (Fig. 1D), suggesting a virus-
specific antiviral activity. We also tested the antiviral activity of
IL-4 against HCoV-NL63, another coronavirus that also uses
the ACE2 receptor to enter the cell (Hofmann et al., 2005).
Compared to untreated control cells, viral excretion from in-
fected Vero E6 cells was reduced by more than 1 log after IL-4
treatment (Fig. 2).Fig. 1. Susceptibility of Vero E6 cells to SARS-CoVor HSV-1 infection after treatm
Triangle-shaped symbols represent SARS-CoV and rectangular symbols represent H
infection, while the right Y-axis represents the number of infected cells per well afteAntiviral activity of IL-4 against SARS-CoV
We further evaluated the antiviral effect of IL-4 against
SARS-CoV using a SARS-CoV-specific RT-PCR and plaque
titration on Vero E6 cells. After pretreatment of the cells with
10 ng/ml IL-4 for 48 h and subsequent infection, excretion of
SARS-CoV from the treated cells was diminished by 1 log, just
as SARS-CoV RNA levels in these cells (Figs. 3A–B). The
antiviral effect of IL-4 was abrogated after preincubation with a
neutralizing IL-4 antibody (Figs. 3A, B). These results further
demonstrate that IL-4 has a modest antiviral activity against
SARS-CoV infection in Vero E6 cells.
To determine which step of the SARS-CoV life cycle is
affected by IL-4, conditioned medium from Vero E6 cells that
were treated with IL-4 (10 ng/ml) was removed and the cells
were washed before they were infected with SARS-CoV.ent with TNF-α (A), IFN-γ (B), IFN-γ combined with TNF-α (C) or IL-4 (D).
SV-1. The left Y-axis indicates the number of infected cells per well after HSV
r SARS-CoV (SCV) infection. Error bars indicate standard errors.
Fig. 3. Antiviral activity of IL-4 against SARS-CoV. Plaque titration of supernatant (A) or amount of SARS-CoV RNA (B) present in mock (control), 10 ng/ml IL-4 or
IL-4/α-IL-4-treated cells that were infected with 105 TCID50 SARS-CoV. Susceptibility of IL-4-treated Vero E6 cells to SARS-CoV infection after removal of IL-4
conditioned medium and subsequent washing (C) and susceptibility of fresh Vero E6 cells to SARS-CoVafter receiving IL-4 conditioned medium just before infection
with 105 TCID50 SARS-CoV (D). Error bars indicate standard errors.
Fig. 4. Binding of recombinant SARS-CoV S protein to Vero E6 cells after
treatment with 10 ng/ml IL-4 (A) or a combination of 10 ng/ml IFN-γ and
10 ng/ml TNF-α (B). Dotted lines represent cytokine-treated cells, while thick
lines represent mock-treated control cells. The shaded areas represent back-
ground staining.
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after 48 h of treatment still conferred protection against SARS-
CoV (Fig. 3C). On the other hand, when this IL-4 conditioned
medium was transferred to fresh untreated Vero E6 cells and
these cultures were infected 5 min later by adding 105 TCID50
SARS-CoV to the medium, no reduction in the number of
SARS-CoV infected cells was observed (Fig. 3D). Therefore,
the presence of a soluble SARS-CoV-infection blocking
molecule, released by IL-4-treated cells, is unlikely. Because
residual IL-4 was still present in this conditioned medium (not
shown), IL-4 probably does not inhibit replication of SARS-
CoV once it has entered the cell and needs to be added to the
cells at an earlier time point. Thus, IL-4 most likely has an
antiviral effect on an early step of the SARS-CoV life cycle in
Vero E6 cells.
Binding of recombinant SARS-CoV spike protein to
cytokine-treated Vero E6 cells
Since IL-4 treatment reduced excretion of virus, viral
replication and infection, only when administered before
SARS-CoV infection, binding of the SARS-CoV S protein to
cytokine-treated Vero E6 cells was analyzed using flow
cytometry. As shown in Fig. 4A, treatment with IL-4 reduced
the ability of Vero E6 cells to bind recombinant S protein.
Because IFN-γ combined with TNF-α also reduced suscept-
ibility of Vero E6 cells to SARS-CoV, we analyzed binding of
the S protein to these cells after IFN-γ/TNF-α treatment and
demonstrated that 10 ng/ml IFN-γ/TNF-α reduced the binding
capacity of the S protein to a background level (Fig. 4B). These
data suggest that these cytokines influence expression of the
cellular receptor for SARS-CoV, ACE2.Effect of cytokine treatment on ACE2 expression
To examine if IL-4 and IFN-γ/TNF-α decrease susceptibility
to SARS-CoV infection through an effect on cell surface ACE2
expression, we analyzed ACE2 expression after cytokine
treatment. As shown in Fig. 5A, 10 ng/ml IL-4 downregulated
ACE2 expression and preincubation with a neutralizing IL-4
antibody abolished the IL-4 effect (Fig. 5B). Similarly,
treatment of Vero E6 cells with 100 ng/ml IL-13− also a Th2
cytokine−downregulated ACE2 expression and inhibited
SARS-CoV replication (data not shown). Background staining
was determined by incubating the cells with normal goat serum
followed by the secondary antibody (Fig. 5).
Fig. 5. Influence of cytokine treatment on ACE2 expression. ACE2 expression was determined after treatment with 10 ng/ml IL-4 (A), IL-4 preincubated with a
neutralizing antibody (B), 10 ng/ml TNF-α (C), 10 ng/ml IFN-γ (D) or 10 ng/ml IFN-γ combined with 10 ng/ml TNF-α (E), all at 48 h. Vero E6 cells were incubated
for 96 h in the presence of 10 ng/ml IFN-γ combined with 10 ng/ml TNF-α (F). HLA-A, B, C expression on Vero E6 cells after treatment with 10 ng/ml IL-4 (G) or
IFN-γ combined with TNF-α (H). Dotted lines represent cytokine-treated cells, while thick lines represent mock-treated control cells. The shaded areas represent
background staining.
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observed after treatment with a combination of 10 ng/ml IFN-γ
and 10 ng/ml TNF-α compared to treatment with these
cytokines separately (Figs. 5C–E). After removal of the
cytokines, ACE2 expression was restored only gradually to
pretreatment levels (data not shown) whereas addition of fresh
IFN-γ and TNF-α at 48 h further decreased ACE2 expression to
background level (Fig. 5F). Downregulation of ACE2 was not
caused by an overall inhibitory effect on cell surface protein
expression; IFN-γ and IL-4 both upregulated MHC class I
expression on Vero E6 cells (Figs. 5G and H).
When ACE2 expression on Vero E6 cells was followed in
time after treatment with IL-4, a gradual decrease in ACE2
expression was observed, which was maximal at 48 h after
treatment (Fig. 6A). The decrease in ACE2 expression over time
correlated with decreased susceptibility to SARS-CoV infection
(Fig. 6B). These experiments also demonstrate that IL-4 only
displayed antiviral activity when administered at least 24 h
before infection with SARS-CoV (Fig. 6B). In contrast,
treatment with IFN-α 1 h after SARS-CoV infection reduced
replication by at least 1 log (not shown). These results further
substantiate our hypothesis that IL-4 inhibits SARS-CoV
replication through downregulation of ACE2.
ACE2 mRNA levels after cytokine treatment
The fact that ACE2 downregulation after IL-4 treatment is a
gradual process and that ACE2 expression recovers slowlywhen cytokines are removed suggests that ACE2 is down-
regulated at the mRNA level. Using an ACE2-specific Taqman,
we observed reduced ACE2 mRNA levels in Vero E6 cells after
48 h of IL-4 or IFN-γ/TNF-α treatment (Fig. 7). This implicates
that downregulation of ACE2 by these cytokines is regulated at
transcription level.
Discussion
It is well established that IFNs inhibit replication of many
different viruses, including SARS-CoV (Cinatl et al., 2003;
Haagmans et al., 2004; Morgenstern et al., 2005; Sainz et al.,
2004). When IFNs bind to their receptors, downstream
signaling from these receptors can block one or more steps in
the virus life cycle. IL-4 on the other hand does not induce these
proteins and may even antagonize the protective effects of IFN
(Lohoff et al., 1990). In general, the Th2-derived cytokine IL-4
is not considered to display antiviral activity. In fact, only a few
studies have demonstrated IL-4 mediated inhibition of viral
replication (Goletti et al., 2002; Lin et al., 2003). Furthermore,
expression of IL-4 by recombinant ectromelia virus or vaccinia
virus exacerbated infection in vivo and the administration of
recombinant IL-4 delayed virus clearance in influenza virus-
infected mice (Jackson et al., 2001; Moran et al., 1996; Sharma
et al., 1996). In this study, we demonstrate that treatment of
Vero E6 cells with IL-4 decreased susceptibility of these cells to
SARS-CoV infection by 10-to 100-fold. Interestingly, ACE2
expression on the cell surface was downregulated after
Fig. 7. ACE2 mRNA levels in Vero E6 cells after treatment with 10 ng/ml IL-4
or a combination of 10 ng/ml IFN-γ and 10 ng/ml TNF-α compared to ACE2
mRNA levels in untreated control cells. ACE2 mRNA levels in untreated
control cell and in IL-4-treated cells are represented as the fold change in gene
expression relative to the IFN-γ/TNF-α-treated cells, which were used as the
calibrator. GAPDH was used as an endogenous control.
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and IFN-γ may decrease susceptibility to SARS-CoV infection
partially through modulation of ACE2 cell surface expression.
Cytokine-mediated downregulation of viral receptors has been
reported earlier in the case of the coxsackievirus–adenovirus
receptor, which can be downregulated synergistically by IFN-γ
and TNF-α in vitro (Vincent et al., 2004).
In this study, we show that the antiviral activity of IL-4 was
not observed when IL-4 was added after SARS-CoV infection.
This suggests that IL-4 inhibits entry of the virus, possibly
through an effect on the viral receptor ACE2. In line with these
observations, IL-4 does not have an antiviral effect against HSV,
but does show antiviral activity against HCoV-NL63, which
also utilizes ACE2 as a receptor. Subsequent experiments re-
vealed that ACE2 expression indeed is downregulated by IL-4.
Confirmation of ACE2's involvement as an intermediate of the
IL-4 antiviral activity is hard to proof because of its essential
role in SARS-CoV infection.
ACE2 is a component of the renin–angiotensin system and
enzymatically cleaves angiotensin I into angiotensin 1–9 and
angiotensin II into angiotensin 1–7 (Donoghue et al., 2000;
Vickers et al., 2002). Several studies have reported regulation of
ACE2 expression, most likely related to its enzymatic activity.
ACE2 protein expression is downregulated in the kidneys ofFig. 6. ACE2 expression and SARS-CoV susceptibility at different time points
after IL-4 treatment. ACE2 expression on Vero E6 cells was monitored at
different time points after IL-4 treatment relative to control cells (A).
Susceptibility of Vero E6 cells to SARS-CoV was monitored at different time
points before and after treatment with 10 ng/ml IL-4 (B). Shown is the number of
SARS-CoV infected cells per well.hypertensive or diabetic rats (Crackower et al., 2002; Tikellis et
al., 2003), whereas ACE2 upregulation has been demonstrated
after blocking of the angiotensin II-receptors in the kidneys of
rats during pregnancy, and in the human failing heart
(Brosnihan et al., 2003; Crackower et al., 2002; Goulter et al.,
2004; Ishiyama et al., 2004; Tikellis et al., 2003). Furthermore,
it was recently shown that ACE2 is downregulated in the lungs
of mice after acute lung injury, including SARS-CoV infection
(Kuba et al., 2005). Most probably, ACE2 can be regulated by
several different factors and expression of this protein is
dynamic on various cell types. Recently it was reported that
ACE2 expression is dependent on the differentiation state of
epithelia; ACE2 was poorly expressed on undifferentiated
airway epithelial cells, while it was abundantly expressed on
well-differentiated cells (Jia et al., 2005). It will be of interest to
study the effect of IL-4 and IFN-γ on ACE2 expression on these
cells.
The ACE2 downregulation was cytokine-specific; while
IFN-γ and IL-4 both downregulated ACE2 expression, IFN-α,
a cytokine that inhibits SARS-CoV replication in vivo and in
vitro, did not affect ACE2 expression on Vero E6 cells (data not
shown). Treatment of Vero E6 cells with IL-13 on the other
hand also downregulated ACE2, suggesting the involvement of
the IL-4 type II receptor in the IL-4 induced antiviral activity.
However, this hypothesis could not be further substantiated
because antibodies against the IL-4 type II receptor tested were
not reactive on non-human primate Vero E6 cells.
Forced downregulation of ACE2 expression by cytokines
may reveal a novel antiviral strategy against SARS-CoV
infection. Potentially, addition of cytokines able to down-
regulate ACE2 expression could further improve the efficacy of
IFN-α based anti SARS-CoV therapy. However, downregula-
tion of ACE2 may have a potential negative effects on SARS
pathogenesis, since it was recently reported that ACE2 has a
protective role in acute lung failure in mice (Imai et al., 2005).
Therefore it will be necessary to explore the consequences of
ACE2 downregulation on SARS pathogenesis.
The most important finding of this study is the observation
that cytokines modulate ACE2 expression. The physiological
relevance of the IL-4 induced antiviral activity may be limited
because this cytokine is probably not produced in large
479A. de Lang et al. / Virology 353 (2006) 474–481quantities during natural SARS-CoV infection (Huang et al.,
2005; Wong et al., 2004). However, vaccination strategies
utilizing inactivated SARS-CoV or subunits in the presence of
specific alum based adjuvants may skew immune response to
TH2 or TH0, allowing the production of IL-4 upon restimula-
tion (Spruth et al., 2006). The relevance of ACE2 expression
modulation by IFN-γ in the pathogenesis of SARS and NL-63
CoV needs further investigation.
Materials and methods
Cells and cytokine treatment
Vero E6 cells (ATCC) were grown in Dulbecco's modified
Eagle's medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), sodium bicarbonate and 20 mM HEPES buffer.
Unless stated otherwise, recombinant human (r-hu) IL-4 (BD
Pharmingen), r-hu IFN-γ, r-hu TNF-α, r-hu IL-13, r-hu IL-10
(Peprotech Inc.) and r-hu IFN-α (Roche) were added to cell
cultures at a concentration of 10 ng/ml, 48 h before infection. As
a specificity control, r-hu IL-4 was preincubated with a
neutralizing IL-4 antibody (Ebiosciences) for 30 min at 37 °C
before addition to the cells. All treatments were done in
quadruplets (96-well experiments) or triplicate (6-well and 24-
well experiments).
Infection of Vero E6 cells and immunohistochemistry
Vero E6 cells grown in 96-well plates were infected with 105
50% tissue culture infective doses (TCID50) SARS-CoV (HKU-
39849) or HSV-1, by adding the virus directly to Vero E6 cell
cultures. After 16 h, cells were fixed with 10% neutral-buffered
formalin and treated with 70% ethanol (10 min RT). SARS-
CoV infected cells were visualized using purified human IgG
from a convalescent SARS patient (CSL), followed by staining
with an antibody to human IgG, linked to horseradish
peroxidase (Amersham Biosciences). HSV-infected cells were
stained using a rabbit anti HSV-1 antiserum, followed by
staining with an antibody to rabbit IgG, linked to horseradish
peroxidase (DAKO).
In the case of the HCoV-NL63 infection, Vero E6 cells
cultured in the presence or absence of IL-4 were infected with
104 TCID50 HCoV-NL63. The inoculum was removed after 1 h
and replaced with fresh medium. After 48 h, the supernatant
from these cells was titrated on fresh Vero E6 cells.
Antiviral activity of IL-4 against SARS-CoV was deter-
mined by plaque titration. Vero E6 cells were grown in 24-well
plates in the presence or absence of IL-4 and infected with 105
TCID50 SARS-CoV. After 1 h, the inoculum was removed and
fresh medium was added. Supernatant from these cultures was
taken at 16 h and plaque titrated by inoculating fresh Vero E6
cells, cultured in 6-well plates, for 1 h. Subsequently, cells
were washed and culture medium containing 0.5% low
melting point agarose was added. The plates were incubated
at 37 °C for 3 days, plaques were counted in wells containing
approximately 10–100 plaques and the results were expressed
as PFU/ml.SARS-CoV and ACE2 RT-PCR
RT-PCR with primers and probe specific for the nucleopro-
tein gene of SARS-CoV was used to quantify SARS-CoV in
infected cells, as described earlier (Kuiken et al., 2003). Serial
dilutions of the SARS-CoV stock were used as a standard.
ACE2 mRNA levels were determined using the ACE2
Taqman Gene Expression Assay (Applied Biosystems). Differ-
ences in ACE2 expression were represented as the fold change
in gene expression normalized to a reference, using the 2−ΔΔCt
method (Livak and Schmittgen, 2001). The housekeeping gene
GAPDH was used as the reference and the IFN-γ/TNF-α-
treated cells were used as the calibrator, since those cells had the
lowest ACE2 expression.
Spike protein binding studies
Binding of the SARS-CoV S protein was analyzed using
flow cytometry. A His-tagged S protein (Protein Sciences) was
incubated with cytokine-treated and mock-treated Vero E6 cells
for 1 h at 4 °C, followed by αHis-FITC (Invitrogen) staining, to
detect binding of the S protein.
ACE2 expression studies
Vero E6 cells, with or without cytokine treatment, were
stained with a polyclonal goat αACE2 antibody (R&D
Systems) followed by staining with an anti-goat-FITC antibody
(Sigma). As a control for background staining of the αACE2
antibody, cells were incubated with normal goat serum (MP
Biomedicals). Staining of the ACE2 receptor on Vero E6 cells
could be blocked with soluble ACE2 protein (R and D systems),
but not with the soluble ACE protein (R&D systems),
demonstrating the specificity of the ACE2 antibody (data not
shown).
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